
Retinal detachment (RD) disrupts oxygen and nutrient delivery to the neurosensory retina, creating a hypoxic environment that can lead to degeneration of photoreceptors (PRs) if left untreated. Hypoxia-inducible factors (HIFs) are central regulators of cellular adaptation to hypoxia, acting to preserve cellular function following oxygen deprivation. We hypothesized that pharmacologic stabilization of HIF1α would protect PRs from hypoxia-induced cell death. To test this, we used the murine cone photoreceptor-like 661 W cell line to evaluate a novel cyclometalated iridium(III) complex, stabilizer 1a, which disrupts the von Hippel-Lindau (VHL)–HIF1α interaction and reduces HIF1α degradation. We compared its effects with dimethyloxalylglycine (DMOG), a well-established cell-permeable inhibitor of HIF prolyl hydroxylase. Stabilizer 1a increased HIF1α accumulation under normoxia and hypoxia and significantly reduced apoptosis induced by hypoxic stress, as demonstrated by reduced cleaved caspase-3 expression and annexin V labeling. Stabilizer 1a was also associated with reduced mitochondrial and total reactive oxygen species (ROS) levels, preserved intracellular ATP levels, and increased markers associated with mitophagy. In addition, stabilizer 1a induced a reversible senescence-like phenotype characterized by increased protein levels of p16 and p21, reduced proliferation, and activation of IL-6 and c-Jun N-terminal kinase (JNK) signaling. Removal of stabilizer 1a restored p21 levels to baseline, supporting a potentially transient adaptive state in response to stress. Further in vivo validation supported these in vitro findings: stabilizer 1a attenuated PR apoptosis after RD, accompanied by increased markers of mitophagy. Together, these findings suggest that short-term HIF1α stabilization with stabilizer 1a is associated with suppression of apoptosis, attenuation of oxidative stress and induction of a transient senescence-like cellular phenotype.
Protein aggregation is increasingly recognized as a fundamental feature of cancer biology, particularly in tumors experiencing chronic proteotoxic stress. TP53 is one of the most frequently mutated genes in human cancers, and many cancer-associated missense mutations promote p53 misfolding and amyloid-like aggregation. These aggregates impair wild-type tumor-suppressive functions while conferring oncogenic gain-of-function (GOF) activities that promote tumor progression and therapeutic resistance. Despite decades of effort, direct pharmacological targeting of mutant p53 has remained challenging because of its structural properties, including the lack of a readily druggable pocket, as well as its extensive mutational heterogeneity. Here, we employed the AUTOTAC platform to target mutant p53 aggregates by exploiting aggregation-associated conformational features characteristic of β-sheet-rich oligomers and protofibrillar aggregates. ATC-37 was designed by linking a methylene blue-derived amyloid-binding ligand, which preferentially recognizes β-sheet-rich protein aggregates, to an autophagy-targeting ligand (ATL) that allosterically activates the autophagy receptor p62/SQSTM1. This design enables engagement of amyloid-like mutant p53 aggregates and promotes their recruitment to autophagosomes. ATC-37 exhibits a dual, concentration-dependent mechanism of action. At low concentrations, it promotes autophagic degradation of mutant p53 aggregates and suppresses downstream GOF signaling. At higher concentrations, it induces p62-dependent sequestration of mutant p53 aggregates that exceeds autophagic capacity, leading to proteotoxic cell death. In a PANC-1 pancreatic cancer xenograft model, ATC-37 significantly inhibited tumor growth, reduced amyloid-like mutant p53 aggregates, and attenuated mutant p53-associated GOF programs. Importantly, ATC-37 also enhanced the response of mutant p53 pancreatic cancer cells to radiation, suggesting potential utility in combination with radiotherapy. These findings establish aggregation-state-directed AUTOTAC therapy as a conceptually innovative, mutation-agnostic strategy for targeting aggregation-prone mutant p53 and potentially other aggregation-prone oncoproteins.
Osteosarcoma patients with metastasis or chemotherapy resistance typically have a poor prognosis, yet the precise mechanisms underlying these adverse clinical outcomes remain elusive. In this study, we analyzed tissue proteomic data from our osteosarcoma cohort to compare protein expression profiles between metastatic and non-metastatic cases, as well as subgroups with low versus high chemotherapy-induced tumor necrosis rates. Our clinical analyses revealed that elevated ubiquitin-specific protease 14 (USP14) expression was associated with lung metastasis, a lower tumor necrosis rate, and shorter overall survival. Functional experiments in vitro and in vivo demonstrated that USP14 knockdown robustly suppressed the proliferation and metastatic potential of osteosarcoma cells. Mechanistically, USP14 interacted with and stabilized integrin β1 via deubiquitination, thereby activating the FAK/SRC axis and inducing inhibitory phosphorylation of GSK3β. This signaling cascade blocked β-catenin ubiquitin-dependent degradation to promote β-catenin accumulation, nuclear translocation, and subsequent activation of TCF/LEF-mediated transcription of downstream oncogenes, ultimately driving osteosarcoma progression. Moreover, chemotherapy upregulated USP14 expression, thereby promoting chemoresistance. Pharmacological inhibition of USP14 with IU1 synergistically enhanced the chemosensitivity of osteosarcoma cells to doxorubicin, effectively restraining tumor growth and metastasis. Collectively, our findings delineate a core USP14-driven oncogenic cascade governing osteosarcoma progression, highlighting USP14 as a promising therapeutic target to improve chemotherapy efficacy and clinical outcomes for osteosarcoma patients.
Atherosclerosis (AS) constitutes the primary underlying etiology of cardiovascular diseases (CVDs), and diabetes mellitus exacerbates the risk of mortality and disability in patients with AS-related CVDs. Given the pivotal role of endothelial cell dysfunction in the progression of diabetic AS plaques, our series of studies has identified that endothelial IDH2 lactylation exerts a cardiovascular protective effect. Lysine residue 272 serves as the specific lactylation site, and the level of this modification is significantly elevated in diabetic plaques. Furthermore, adenovirus was used to infect mouse aortic endothelial cells (MAECs) to abrogate the lactylation activity at the K272 site of IDH2. Experimental results demonstrated that IDH2-K272 lactylation contributes to the maintenance of IDH2 enzymatic activity, thereby ensuring sufficient biosynthesis of α-ketoglutarate (α-KG) and attenuating mitochondrial damage and endothelial dysfunction under hyperglycemic and hyperlipidemic conditions. Additionally, utilizing adeno-associated viruses encoding the K272 site (AAVENT-IDH2-K272R) to abrogate endothelial IDH2 lactylation activity of ApoE–/– male mice, we induced diabetic plaques with streptozotocin (STZ). Concurrently, in endothelial cell-specific IDH2-K272R knock-in (IDH2EC-K272R) male mice, plaques were induced using AAV-PCSK9 and STZ. Both animal models consistently demonstrated that loss of K272 lactylation exacerbates mitochondrial dysfunction and endothelial injury, thereby promoting plaque formation and instability. Furthermore, we validated that exogenous supplementation of α-KG effectively mitigates the progression of diabetic plaques. In summary, our study is the first to reveal that endothelial IDH2-K272 lactylation counteracts diabetic atherosclerosis via α-KG, thereby offering a valuable therapeutic strategy.